Abstract 061: A Multi Center Clinical Experience in Medellin, Colombia Using The Pipeline Vantage Device for the Treatment of Intracranial Aneurysms. Initial Results and One Year Follow‐Up

Background and Purpose Flow diverter technology has evolves trying to provide safe, stability and a good long‐term result. We report a local / regional experience with the fourth generation Pipeline Vantage Embolization Device in the treatment of intracranial aneurysms. Methods We present here a multi‐center, prospective, interventional, single‐arm trial of the Pipeline Vantage Embolization Device for the treatment of intracranial aneurysms. The primary end points were the effectiveness (the complete occlusion rate at 6‐ and 12‐month) and the safety (the presence or absence of serious adverse events during procedure and follow‐up) Univariable and multivariable logistic regression was performed to identify predictors of aneurysm persistence, periprocedural complications, and adverse events during follow‐up. Results Between October 2022 and January 2024, 73 patients harboring 91 intracranial aneurysms were treated in 76 interventions at 6 centers in Medellin, Colombia. Pipeline Vantage Embolization Device placement was technically successful in all patients. Most aneurysms (85.7%) were located at the anterior circulation, and the mean diameter was 6.7 mm. At 6 months, 56 of 70 (80%) aneurysms showed a complete occlusion and one year follow up revealed a complete occlusion in 56/63 (89.2%) Bifurcation aneurysms (odds ratio, 5.66; 95% CI, 1.01‐31.77) and the presence of a branch arising from the sac (odds ratio, 6.36; 95% CI, 2.11‐22.36) predicted persistence. A mild Neointimal hyperplasia (i.e < 25%) was evidenced in 10/63 (15.8%) and significant (i.e >50%)in 3/63. Of the 73 enrolled patients, 69 (94.5%) were treated without serious adverse events during the procedure or during the follow‐up. No mortality procedural related. Conclusions The treatment of intracranial aneurysms using the novel Pipeline Vantage Embolization Device was safe and effective. Our findings in terms of complete occlusion rates were similar to those seen in previously published studies with flow diverter devices and earlier generation Pipeline devices.